Babelon Investments Company (P.L.C) (ASE:SALM)

Verve Therapeutics Balance Sheet

Financials in millions JOD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.59	0.58	0.62	0.71	1.01	1.19
Accounts Receivable	0	-	0	0	0	0
Other Receivables	0	0	0.01	0	0.01	0.01
Investments in Debt & Equity Securities	1.64	1.47	1.67	1.49	1.1	0.86
Other Current Assets	-	-	0	0	-	-
Total Assets	2.23	2.05	2.3	2.21	2.11	2.06
Accrued Expenses	-	0	0	0	-	0
Other Current Liabilities	0.02	0.01	0.01	0.01	0.01	0.01
Total Liabilities	0.02	0.02	0.03	0.02	0.02	0.03
Common Stock	2	2	2	2	2	2
Retained Earnings	0.46	0.45	0.49	0.43	0.44	0.5
Comprehensive Income & Other	-0.25	-0.42	-0.22	-0.25	-0.35	-0.47
Shareholders' Equity	2.21	2.03	2.27	2.19	2.09	2.03
Total Liabilities & Equity	2.23	2.05	2.3	2.21	2.11	2.06
Net Cash (Debt)	0.59	0.58	0.62	0.71	1.01	1.19
Net Cash Growth	3.31%	-6.25%	-12.81%	-29.49%	-15.25%	-10.17%
Net Cash Per Share	0.31	0.29	0.31	0.35	0.50	0.59
Filing Date Shares Outstanding	2	2	2	2	2	2
Total Common Shares Outstanding	2	2	2	2	2	2
Working Capital	0.57	0.56	0.6	0.69	0.99	1.18
Book Value Per Share	1.11	1.01	1.14	1.09	1.05	1.02
Tangible Book Value	2.21	2.03	2.27	2.19	2.09	2.03
Tangible Book Value Per Share	1.11	1.01	1.14	1.09	1.05	1.02

Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Capital Markets template. Financial Sources.